Reduced Expression of SFRP1 is Associated with Poor Prognosis and Promotes Cell Proliferation in Breast Cancer: An Integrated Bioinformatics Approach

Abstract

PurposeBreast carcinoma is the most frequent form of malignancy in women globally. Exploration of the breast cancer genome tiled the way for the validation of novel cancer biomarkers and to explore various mechanisms involved in the progression of carcinogenesis. The purpose of the research is to find an identification of potential gene linked to breast cancer (BC) progression and prognosis. MethodsThree datasets (GSE71053, GSE61724, and GSE36295) were downloaded from the Gene Expression Omnibus (GEO) database. An integrated analysis of several gene expression profile datasets was used to find differentially expressed genes (DEGs) in BC and normal breast tissue samples. Protein–protein interaction (PPI) network was used to verify hub genes associated with the pathogenesis and prognosis of BC. The functional enrichment and pathway analysis was performed by FunRich and cBioPortal. The expression pattern was assessed using COSMIC, GEPIA2, and BC-GenExMiner. ResultsThe results revealed that among the hub genes, Secreted Frizzled-related protein 1 (SFRP1) was a negative regulator of the Wnt pathway in breast cancer. Loss of SFRP1 may result in abnormal cellular proliferation, migration, and invasion, which may trigger cancer cells, leading to progression of the disease, poor prognosis, and therapy resistance. Lastly, the Kaplan–Meier plotter online database demonstrated that expression levels of the SFRP1 gene were related to lower survival. ConclusionThe findings of this research would provide some directive significance for further investigating the diagnostic and prognostic biomarker to facilitate the molecular targeting therapy of breast cancer; SFRP1 expression may be effective as a novel prognostic biomarker in early breast cancer.